Digest Network Come funziona
Network
/
Società
Ni
Non verificato

NiKang Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

4 comunicati stampa

Guarda tutti i comunicati
08/09/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader
Fonte
NiKang Therapeutics
Emittente
Business Wire
1.00
0
10/03/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 Degrader
Fonte
NiKang Therapeutics
Emittente
Business Wire
1.00
0
21/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
Fonte
NiKang Therapeutics
Emittente
Business Wire
1.00
0
09/09/2024
Eventi
Fiere
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
NiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress
Fonte
NiKang Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0